Elafibranoris also known as GFT-505. It is an agonist of the peroxisome proliferator-activated receptor and peroxisome proliferator-activated receptor. It is used for study for the treatment of cardiometabolic diseases. It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. It is also studied for the treatment of diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease.
Description of elafibranor
It is an experimental medication and is being studied and developed by Genfit. It induces resolution of nonalcoholic steatohepatitis without fibroisis worsening. The safety and efficacy of ELAFIBRANOR powder had been assessed.
The application of elafibranor
it is a multimodal and pluripotent medication. It is used for the treatment of atherogenic dyslipidemia for an overweighted patient whether suffering from diabetes or not. Research and study keep going on this powder. Till date, 8 clinical trials have been completed and phase 3 is in progress.
Confirmation in clinical studies in NASH
It is observed that treatment with elafibranorpromoted:-
- Cardioprotective lipid profile.
- Decreased markers of liver injury.
- Anti-inflammatory properties.
- Glucose homeostasis.
Elafibranor evaluation of hepatic lipid composition for NAFL
The objective of this study was to determine the effect of elafibranor on fatty acid saturation. NAFL refers to the condition associated with an accumulation of fat in the liver.
What is the mechanism of action?
ELAFIBRANORpowderis an oral treatment that acts on 3 sub-types of PPAR with preferential action on PPARa. It works on a sophisticated mechanism of action. It is able to identify and profile the activity of selective nuclear receptor modulator. This is considered a powerful approach.
Diseases and its treatment
Non-alcoholic fatty liver disease, fibrosis, inflammation are some of the diseases whose treatment using elafibranor has been done in many cases.
It is investigated for use and treatment in atherosclerosis and diabetes mellitus type 2. Treatment of non-alcoholic fatty liver disease including non-alcoholic steatohepatitis (NASH)
The basic information about ELAFIBRANOR powder is that it is also known as GFT505. Its purity percentage is 98% the chemical name is GFT505; GFT-505; GFT 505. The molecular formula is C22H24O4S. its appearance can be described as white to off-white powder. It is solid in form and soluble in DMSO.
There are many companies who are into the sale of this powder. You can visit their official site and get all the needed information. You can detail about composition, price, etc. The companies also indulge in research and manufacturing and innovation work. Elafibranor is always a matter of research. Researchers are always into the aim of discovering more benefits of this substance. With time and further advancements more and more uses and benefits will be discovered and it will become a more popular medicine for treating diseases.